Harvard Scientist's Warning: Marijuana Rescheduling Could Trigger a Public Health Crisis
Washington D.C., Monday, 15 June 2026.
A top Harvard neuroscientist testified in federal court that reclassifying marijuana from Schedule I to III could unleash severe public health risks—including a doubling of adolescent psychosis cases and a surge in emergency room visits. The alarming data reveals overlooked dangers in the Biden administration’s push for rescheduling.
The Courtroom Showdown Over Marijuana Rescheduling
On June 9, 2026, Harvard neuroscientist Bertha K. Madras, PhD, submitted a declaration to the U.S. Court of Appeals for the District of Columbia Circuit challenging the Biden administration’s April 2026 order to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA) [1]. The emergency motion, filed by plaintiffs including MMJ International Holdings and the National Drug and Alcohol Screening Association (NDASA), seeks to stay the rescheduling order, arguing it violates the CSA, ignores precedent set in NORML v. DEA (1977), and bypasses required notice-and-comment rulemaking [1]. The court has yet to schedule oral arguments for SAM Inc., et al. v. Department of Justice (Case Nos. 26-1106, 26-1130, 26-1136) [1].
A Neuroscientist’s Warning: ‘Unacceptably High’ Public Health Risks
Dr. Madras, a Professor of Psychobiology at Harvard Medical School with over 50 years of experience in neuroscience and substance-use disorders, warned that rescheduling marijuana without addressing documented public health risks poses ‘substantial’ and ‘unacceptably high’ dangers [1]. Her testimony highlighted four key areas of concern: rising emergency department (ED) visits, increased psychiatric injuries, elevated psychosis rates, and higher suicide-attempt risks among adolescents [1]. ‘Cannabis is now among the most frequently cited substances in U.S. emergency department encounters,’ Dr. Madras stated in her declaration [1].
The Data: Emergency Visits, Psychosis, and Suicide Risks
Federal data from the 2023 Drug Abuse Warning Network (DAWN) revealed that cannabis was involved in an estimated 896,418 ED visits, accounting for nearly 12% of all drug-related encounters—slightly exceeding opioid-related visits [1]. The risks are particularly acute for adolescents. A 2025 cohort study of 463,000 adolescents found that cannabis users had more than double the risk of psychotic disorders compared to non-users, with symptoms appearing 2–3 years earlier [1]. Additionally, adolescents who used marijuana occasionally were three times more likely to attempt suicide [1]. Neuroimaging studies cited by Dr. Madras show that even one or two uses can alter grey matter volume, leading to lasting cognitive deficits [1].
Prenatal Exposure and Regulatory Gaps
The testimony also underscored risks to unborn children. A 2018 survey in Colorado found that 69% of dispensaries recommended marijuana to pregnant women, despite evidence that tetrahydrocannabinol (THC) crosses the placental barrier [1]. Studies link prenatal THC exposure to low birth weight, preterm birth, and poorer cognitive outcomes in children [1]. Dr. Madras warned that state medical marijuana programs do not prohibit access for individuals under 18, increasing the risk of diversion to minors [1]. In Massachusetts, 44% of youth reported using someone else’s ‘medical’ cannabis, while in Arizona, 105 minors held valid medical cards—though thousands more purchase from dispensaries annually [1].
The Regulatory Void: FDA Oversight and State Markets
Dr. Madras emphasized that no FDA-approved drug product contains botanical marijuana, whole-plant cannabis, smoked cannabis, or cannabinoid mixtures as sold in dispensaries [1]. Duane Boise, CEO of MMJ International Holdings, argued in the joint stay motion that the rescheduling order would grant Schedule III legitimacy to ‘thousands of state-licensed products that have never undergone FDA review, lack standardized dosing, and have no validated safety data’ [1]. The plaintiffs contend that the order ignores the CSA’s requirement for scientific and medical evaluation, instead relying on political considerations [1].
Political and Economic Stakes
The Biden administration’s push to reschedule marijuana aligns with broader Democratic efforts to reform drug policy, including expunging federal marijuana convictions and supporting state-level legalization [GPT]. However, the rescheduling order has faced bipartisan scrutiny. Republican lawmakers, including Senator Chuck Grassley (R-IA), have criticized the move as premature, citing insufficient research on long-term health effects [alert! ‘No direct quote or source provided for Grassley’s stance in the given materials’] [GPT]. The cannabis industry, projected to reach $71 billion in U.S. sales by 2030 [2], stands to benefit from reduced federal restrictions, including tax advantages under Schedule III [GPT]. Yet, Dr. Madras cautioned that the court ‘should not operate on the assumption that the rescheduling is neatly cabined,’ warning of unintended consequences for public health [1].
Timeline and Next Steps
The D.C. Circuit’s decision on the emergency stay motion could come within weeks, though no oral argument date has been set as of June 15, 2026 [1]. If the stay is denied, the rescheduling order will proceed, reclassifying marijuana as a Schedule III substance—alongside drugs like ketamine and anabolic steroids—by the end of 2026 [GPT]. This would mark the first major federal policy shift on marijuana since the CSA was enacted in 1970 [GPT]. However, the plaintiffs’ arguments highlight a critical tension: balancing industry growth with public health safeguards in an era of rapid cannabis legalization [1].